Idiopathic Pulmonary Fibrosis Clinical Trials

19 studies are recruiting for idiopathic pulmonary fibrosis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

   This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution comp…

   Stage

   Phase 2

   Ages

   40 and older

   Site

   University of Florida, Gainesville, Florida

   Locations

   46 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07036523 on ClinicalTrials.gov

2. Pulmonary Fibrosis Foundation Community Registry

   Pulmonary fibrosis (PF) results from a diverse group of health conditions and affects the lives of patients (including those who are post lung transplant), caregivers and family members. The Pulmonary Fibrosis Foundation Community Registry will offer an online portal where participants can self-enr…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Pulmonary Fibrosis Foundation, Chicago, Illinois

   Run by

   Pulmonary Fibrosis Foundation

   See if you can join NCT05382572 on ClinicalTrials.gov

3. A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

   The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF). It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study. A to…

   Stage

   Phase 2

   Ages

   40 and older

   Site

   Hannibal Regional Healthcare System, Inc., Hannibal, Missouri

   Locations

   3 in total

   Run by

   Chiesi Farmaceutici S.p.A.

   See if you can join NCT07516951 on ClinicalTrials.gov

4. Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

   The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Newportnativemd, Inc., Newport Beach, California

   Locations

   19 in total

   Run by

   Trevi Therapeutics

   See if you can join NCT07671911 on ClinicalTrials.gov

5. Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

   Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatme…

   Stage

   Phase 2

   Ages

   40 and older

   Site

   The University of Alabama at Birmingham /ID# 277613, Birmingham, Alabama

   Locations

   57 in total

   Run by

   AbbVie

   See if you can join NCT07230288 on ClinicalTrials.gov

6. Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

   Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

   Stage

   Phase 2

   Ages

   40 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   20 in total

   Run by

   Cumberland Pharmaceuticals

   See if you can join NCT05571059 on ClinicalTrials.gov

7. Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

   The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are like…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Michelle F MacPherson, Pittsburgh, Pennsylvania

   Run by

   University of Pittsburgh

   See if you can join NCT00373841 on ClinicalTrials.gov

8. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

   This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California Davis, Sacramento, California

   Locations

   373 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06238622 on ClinicalTrials.gov

9. Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

   The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose ([18F] FDG) and fluorine-18 Displacement Per Atom ([18F]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmo…

   Stage

   Phase 1

   Ages

   40 to 85

   Site

   The University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT04362644 on ClinicalTrials.gov

10. Dose-Escalation Study of Artesunate Patients With IPF

    Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring . This will be a single-center randomized, double-blinded, placebo-controlled study of 20 weeks including …

    Stage

    Phase 1

    Ages

    40 and older

    Site

    Stanford University, Stanford, California

    Run by

    Joseph C. Wu

    See if you can join NCT05988463 on ClinicalTrials.gov

11. WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

    Stage

    Phase 2

    Ages

    40 and older

    Site

    WISPer Site in Birmingham, AL, Birmingham, Alabama

    Locations

    71 in total

    Run by

    Mediar Therapeutics

    See if you can join NCT06967805 on ClinicalTrials.gov

12. H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

    Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die i…

    Stage

    Phase 2

    Ages

    18 to 100

    Site

    NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina

    Run by

    National Institute of Environmental Health Sciences (NIEHS)

    See if you can join NCT06325696 on ClinicalTrials.gov

13. Interstitial Lung Disease Research Unit Biobank

    Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of Kansas Medical Center, Kansas City, Kansas

    Run by

    University of Kansas Medical Center

    See if you can join NCT05392881 on ClinicalTrials.gov

14. A Study of the Natural Progression of Interstitial Lung Disease (ILD)

    We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of the…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Chicago, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT00470327 on ClinicalTrials.gov

15. Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

    The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.

    Stage

    Phase 1

    Ages

    18 to 60

    Site

    UPMC Presbyterian, Pittsburgh, Pennsylvania

    Locations

    2 in total

    Run by

    Paul Szabolcs

    See if you can join NCT03500731 on ClinicalTrials.gov

16. Mechanisms of Familial Pulmonary Fibrosis

    This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP). FIP is the familial form of idiopathic pulmonary fibrosis (IPF), which is defined as 2 or more bloodline relatives which have a diagnosis of idiopathic interstitia…

    Stage

    Not phased

    Ages

    40 to 75

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT03437486 on ClinicalTrials.gov

17. Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

    The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are: Can the investigators recruit particip…

    Stage

    Phase 2

    Ages

    50 and older

    Site

    Cedars-Sinai, Los Angeles, California

    Run by

    Cedars-Sinai Medical Center

    See if you can join NCT06567717 on ClinicalTrials.gov

18. Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis

    Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Snyder Building 480 Ray C. Hunt Drive, Charlottesville, Virginia

    Run by

    University of Virginia

    See if you can join NCT06853145 on ClinicalTrials.gov

19. The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

    This observational study involves obtaining 2 chest CT scans; a historical baseline CT within ±1 year of enrollment into PRECISIONS, and a follow-up CT (either historical or prospective) 12 months ± 180 days after the baseline CT. Many IPF patients will have a CT scan every 12 months for disease mo…

    Stage

    Not phased

    Ages

    40 to 101

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    University of Virginia

    See if you can join NCT06323876 on ClinicalTrials.gov